BioSpace News Archive

Shanghai Fosun Pharmaceutical Co., Ltd., a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its interim results for the first half of 2022.

Xcelerate, Inc. announced that it had begun an initiative to identify marketing/manufacturing partners to assist in the development of over-the-counter healthcare products based on its existing patent portfolio.

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser.

Y-mAbs Therapeutics, Inc. and Takeda Israel, announced today that the Israeli Ministry of Health has approved DANYELZA in Israel for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Avantor, Inc. (NYSE: AVTR), announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York Hotel in New York on Monday, September 12, at approximately 4:15 p.m. Eastern Daylight Time.

Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

The regenerative medicine company Seraxis Inc. announced the appointment of Paul Strumph, M.D. as Chief Medical Officer.

Opthea Limited reported financial results for the fiscal year ended June 30, 2022 and provided an overview of recent progress.

I-Mab will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m. ET and an English session will be held at 8:15 a.m. ET.

Revision Skincare®, a leading medical-grade professional skincare brand, announced a partnership with RVL Pharmaceuticals plc, the owner of UPNEEQ®, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis in adults.